| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/23/2002 | CA2429460A1 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 05/23/2002 | CA2429144A1 Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant |
| 05/23/2002 | CA2429140A1 Antibody against norwalk virus and method of detecting virus by using the antibody |
| 05/23/2002 | CA2429100A1 Parenterally administrable microparticles |
| 05/23/2002 | CA2428721A1 Blockade of t cell migration into epithelial gvhd target tissues |
| 05/23/2002 | CA2427902A1 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 05/23/2002 | CA2427010A1 Transporters and ion channels |
| 05/22/2002 | EP1207205A1 Adenoviral replicons |
| 05/22/2002 | EP1207203A2 DNA sequence and papillomavirus vaccine |
| 05/22/2002 | EP1207199A1 Tumor antigen |
| 05/22/2002 | EP1206702A1 Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody |
| 05/22/2002 | EP1206701A1 Antigenic components of selected indicator fungi and their use in methods and test kits |
| 05/22/2002 | EP1206563A1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 05/22/2002 | EP1206553A2 Isomerase proteins |
| 05/22/2002 | EP1206550A1 Proteins derived from white spot syndrome virus and uses thereof |
| 05/22/2002 | EP1206549A1 Basb119 polypeptide and polynucleotide from moraxella catarrhalis |
| 05/22/2002 | EP1206548A1 Basb118 polypeptide and polynucleotide from moraxella catarrhalis |
| 05/22/2002 | EP1206547A2 Moraxella catarrhalis antigen basb117 |
| 05/22/2002 | EP1206546A2 Moraxella catarrhalis antigen basb120 |
| 05/22/2002 | EP1206545A1 Basb116 dna and proteins from moraxella catarrhalis |
| 05/22/2002 | EP1206535A1 Tumor-associated antigen (r11) |
| 05/22/2002 | EP1206529A2 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-BETA 1,3-N-ACETYLGALACTOSAMINE-ALPHA-R/(GlcNAc to GalNAc) BETA 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3 |
| 05/22/2002 | EP1206495A1 Chimeric polypeptides, method for production and uses thereof |
| 05/22/2002 | EP1206491A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 05/22/2002 | EP1206488A2 Method for isolating and purifying grass pollen allergens |
| 05/22/2002 | EP1206487A2 Notch receptor ligands and uses thereof |
| 05/22/2002 | EP1206482A2 Method for coupling, in solution, a peptide with at least another compound and uses thereof |
| 05/22/2002 | EP1206278A2 Peptide mixture and vaccine against a chronic viral infection |
| 05/22/2002 | EP1206277A1 Methods and materials for the treatment of prostatic carcinoma |
| 05/22/2002 | EP1206274A2 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 05/22/2002 | EP1206251A1 Amplification of folate-mediated targeting to tumor cells using nanoparticles |
| 05/22/2002 | EP1206250A2 Pharmaceutical formulations with different release times |
| 05/22/2002 | EP1206234A2 Methods and compositions for modulating cell proliferation and cell death |
| 05/22/2002 | EP1206233A2 Serine proteases |
| 05/22/2002 | EP1206190A1 Vaccines for the treatment of autoimmune disease |
| 05/22/2002 | EP1206189A1 Rotavirus vaccine formulations |
| 05/22/2002 | EP1107996B1 HUMAN ANTI-FACTOR IX/IXa ANTIBODIES |
| 05/22/2002 | EP0746329B1 Anti-inflammatory factor containing compositions, method of production, and use |
| 05/22/2002 | EP0606317B1 Saponin-antigen conjugates and the use thereof |
| 05/22/2002 | CN1350585A i(Neisseria meningitidis) polypeptide BASBO52 |
| 05/22/2002 | CN1350578A Recombinant influenza viruses for vaccines and gene therapy |
| 05/22/2002 | CN1350549A Compositions and methods for generating monoclonal antibodies representative of a specific cell type |
| 05/22/2002 | CN1350547A Alleviation of the alelrgenic potential of airborne and contact allergens by thioredoxin |
| 05/22/2002 | CN1350464A Docetaxel in combination with rhumab HER2 for the treatment of cancers |
| 05/21/2002 | US6392029 HIV chemokines |
| 05/21/2002 | US6392028 Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| 05/21/2002 | US6392026 Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins |
| 05/21/2002 | US6392023 Nucleotide sequences which codes preferential polypeptide for use in serodiagnostics and vaccine development |
| 05/21/2002 | US6392020 Monoclonal antibody to the clonotypic structure of a T-cell receptor, a pharmaceutical compostion and a diagnostic reagent comprising the same |
| 05/21/2002 | US6392016 Preferential polypeptide for use in the diagnosis and treatment of tumors; antiproliferative agents |
| 05/21/2002 | US6392014 Cloning of gene encoding the GP28.5 protein of Toxoplasma gondii; peptide fragments of said protein and their applications |
| 05/21/2002 | US6391853 Human tissue inhibitor of metalloproteinase-4 |
| 05/21/2002 | US6391651 Materials and methods for detection of insulin dependent diabetes |
| 05/21/2002 | US6391632 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| 05/21/2002 | US6391600 PcrA helicase |
| 05/21/2002 | US6391587 Nucleotide sequences for use in the prevention of microorganismal infections |
| 05/21/2002 | US6391580 Ras proteins |
| 05/21/2002 | US6391567 Identifying compounds inhibiting DC-sign facilitation of HIV into cells |
| 05/21/2002 | US6391543 Screening sample for preferential nucleotide sequences; incubate sample with nucleotide sequences, monitor sample for signal indicating bound nucleotide sequences |
| 05/21/2002 | US6391318 Composition comprising antigen and effective adjuvant amount of chitosan produced from chitin by deacetylation to degree of greater than 40% and having molecular weight between 10 kd and 500 kd |
| 05/21/2002 | US6391316 Vaccine compositions comprising Haemophilus somnus transferrin-binding proteins and methods of use |
| 05/21/2002 | US6391315 Composition comprising mixed antigens derived from both cell surface extracts and cultured broth, treated by chromatography to obtain effective fraction free of endotoxin and whole cells |
| 05/21/2002 | US6391314 Immunogenic composition comprising vector that contains and expresses in vivo in porcine host cell, nucleic acid molecule or fragment thereof encoding type ii porcine circovirus antigen and pharmaceutically acceptable vehicle or diluent |
| 05/21/2002 | US6391313 Vaccine comprising at least three antigens from hemophilus influenzae and at least one antigen from moraxella catarrhalis to protect against disease caused by both bacteria, including otitis media |
| 05/21/2002 | US6391311 Polypeptide comprising amino acid sequence at least about 80% identical to specified sequence, which has biological activity of promoting selective growth and/or survival of human umbilical vein endothelial cells in in vitro assay |
| 05/21/2002 | US6391306 Treatment of infectious diseases with hsp90-peptide complexes |
| 05/21/2002 | US6391304 Medicinal product capable of inducing protection in feline host against infection with feline immunodeficiency virus, comprising isolated peptide consisting of or containing specified amino acid sequence |
| 05/21/2002 | US6391303 Orally administering to animal pharmaceutical formulation comprising antigen and delivery agent comprising at least one derivatized amino acid or salt thereof in amount sufficient to induce tolerance to antigen |
| 05/21/2002 | US6391301 Agent for identifying and treating metastasizing tumors |
| 05/21/2002 | US6391299 Anti-factor IX/IXa antibodies |
| 05/21/2002 | US6391280 J chain polypeptide targeting molecule linked to an imaging agent |
| 05/21/2002 | CA2153254C Cloning of enterokinase and method of use |
| 05/21/2002 | CA2148595C Molecule labelling using 2-hydrazinopyridine derivatives |
| 05/16/2002 | WO2002039431A2 Compositions and methods relating to prostate specific genes and proteins |
| 05/16/2002 | WO2002039121A2 Methods for detecting the efficacy of anticancer treatments |
| 05/16/2002 | WO2002039117A1 Methods for the treatment of cellular proliferative disorders |
| 05/16/2002 | WO2002038803A2 Novel marker for the diagnosis and therapy of tumours |
| 05/16/2002 | WO2002038769A2 Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2 |
| 05/16/2002 | WO2002038765A2 Dna encoding bovine immunoglobulin a inducing protein and uses therefor |
| 05/16/2002 | WO2002038744A2 Proteases |
| 05/16/2002 | WO2002038742A2 Dipeptidylpeptidases and methods of use |
| 05/16/2002 | WO2002038733A2 A selectable genetic marker for use in pasteurellaceae species |
| 05/16/2002 | WO2002038726A2 Paramyxovirus vector for gene transfer to the cardiovascular system |
| 05/16/2002 | WO2002038612A2 Canine and feline tumour-associated antigen 5t4 |
| 05/16/2002 | WO2002038607A2 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | WO2002038600A2 C. elegans genes involved in viability and/or reproduction and uses thereof |
| 05/16/2002 | WO2002038594A1 Novel therapeutic compositions for treating infection by lawsonia spp |
| 05/16/2002 | WO2002038593A1 Haemophilus antigen |
| 05/16/2002 | WO2002038177A2 Adjuvant combination formulations |
| 05/16/2002 | WO2002038176A2 Immunogenic compositions comprising liver stage malarial antigens |
| 05/16/2002 | WO2002038175A1 Vaccines with enhanced immune response and methods for their preparation |
| 05/16/2002 | WO2002038174A2 Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use |
| 05/16/2002 | WO2002038173A1 Vaccine based on a cellular penetration factor from an apicomplexan parasite |
| 05/16/2002 | WO2002038172A2 Sdf-1 beta expressing tumor cells as tumor vaccines |
| 05/16/2002 | WO2002038169A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 05/16/2002 | WO2002038146A1 Mucosal immunomodulator and use thereof |
| 05/16/2002 | WO2002037961A2 Methods and compositions for the control of coccidiosis |
| 05/16/2002 | WO2002020054A3 Methods of treatment and diagnosis of hcv infection in cns based on magnetic resonance spectroscopy |
| 05/16/2002 | WO2002019968A3 Genetically engineered co-expression dna vaccines, construction methods and uses thereof |
| 05/16/2002 | WO2002012292A3 Method of polypeptide renaturation |